Mergers & acquisitions
The company sold the stake to Sapphire I Holdings at an undisclosed price.
Investors love to speculate on M&A, and one of the hottest topics of speculation recently has been whether someone will buy BMS.
Creat Group will attempt to restructure its $1.5M offer to acquire Biotest after U.S. regulators nixed the deal.
The PE firm made the investment just three years ago.
A little more than two years after acquiring Sprout, Valeant is selling off the developer of the female sex drive drug Addyi.
Tonghua Golden-Horse Pharma and Golden Meditech Holdings -- will submit bids in the second round of an auction to acquire I-MED Radiology.
The acquisition is expected to close by the end of 2017.
Neurocrine’s third-quarter financial results didn’t just impress, they blew everybody away.
Mallinckrodt has agreed to buy Ocera Therapeutics in a deal that could hit $117M.
Days after plunking down $3.9B+ for AAA, Novartis may be looking to divest itself of its generic dermatology drug business.
PRESS RELEASES